Profound Medical (PRN) to Release Quarterly Earnings on Thursday

Profound Medical (TSE:PRN) will issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of C($0.42) per share for the quarter.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, August 8th. The company reported C($0.38) EPS for the quarter, hitting analysts’ consensus estimates of C($0.38). The company had revenue of C$3.06 million during the quarter, compared to analysts’ expectations of C$3.42 million.

Profound Medical Stock Performance

Profound Medical stock opened at C$10.94 on Wednesday. Profound Medical has a fifty-two week low of C$9.55 and a fifty-two week high of C$16.00. The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. The stock has a market cap of C$267.81 million, a P/E ratio of -6.59 and a beta of 0.81. The firm’s fifty day moving average price is C$10.81 and its 200-day moving average price is C$11.51.

Insider Buying and Selling at Profound Medical

In other news, Senior Officer Rashed Osman Dewan acquired 9,765 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was purchased at an average cost of C$12.85 per share, for a total transaction of C$125,480.25. Company insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.